Screener
BridgeBio Pharma BBIO Reportable Segment — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — interest expense, nonoperating?
- BridgeBio Pharma (BBIO) reported reportable segment — interest expense, nonoperating of $12.94M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — interest expense, nonoperating changed year-over-year?
- BridgeBio Pharma's reportable segment — interest expense, nonoperating decreased by 28.6% year-over-year, from $18.12M to $12.94M.
- What does reportable segment — interest expense, nonoperating mean?
- Costs associated with debt financing, including interest payments on loans or bonds that are not directly tied to core operations. It represents the cost of capital for the segment.
Ask your AI about BridgeBio Pharma's reportable segment — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude